How Common Are Blood Clots?
Blood clots are generally rare, but they can occur even in otherwise healthy people, including those who are not taking CHCs. Out of every 10,000 women who are neither pregnant nor using CHCs, between 1 and 5 will experience a blood clot every year. Women using CHCs have a slightly higher risk: between 3 and 9 in every 10,000 CHC users experience a blood clot in a given year.
What Types of Blood Clots Are There?
"Venous blood clots" or "venous thromboembolisms" (VTEs) are a mass of thickened blood inside a vein. Many people are familiar with deep vein thrombosis (DVT) and pulmonary embolism (PE), which are types of VTE. VTEs can travel through the bloodstream, damaging vital organs and even resulting in death. VTEs are the third-most common type of cardiovascular illness in the U.S. and cause 300,000 deaths annually.
Who's at Risk of Getting Blood Clots?
The highest risk of blood clots among reproductive-aged women occurs during pregnancy and in the postpartum period, when estrogen levels increase. Among pregnant women, between 5 and 20 in every 10,000 pregnant women will experience a blood clot in a year; 40 to 65 in every 10,000 postpartum women experience a blood clot in a year.
What Are Combined Hormonal Contraceptives (CHCs)?
Birth control methods that contain the hormones estrogen and progestin are called combined hormonal contraceptives (CHCs). CHC products include birth control pills, patches, and vaginal rings. While all CHCs carry some risk of blood clots, the risk can differ from product to product.
What Are the Signs and Symptoms?
Some people experiencing a blood clot have no signs or symptoms at all. When symptoms do occur, depending on where the blood clot is located in the body, people may experience some or all of the following:
- redness of the skin
- difficulty breathing
- faster than normal or irregular heartbeat
- chest pain or discomfort
- coughing up blood
- very low blood pressure, light-headedness, or fainting
People experiencing any of these symptoms should seek medical care immediately.
So, although CHCs increase the risk of blood clots, the risk is only slightly higher than the risk for women who don't use CHCs, and is significantly lower than the risk faced by pregnant women. Some personal characteristics and medical conditions increase the risk of blood clots, including (but not limited to):
- genetic clotting disorders
- being over age 60
- prolonged inactivity (such as during long car or airplane rides)
Individuals with characteristics that increase their risk of blood clots should discuss the risks of using CHCs with their health care provider and/or pharmacist.
Estrogen increases blood's ability to clot. Taking estrogen-containing CHCs increases the body’s estrogen levels and therefore increases the risk of a blood clot.
Some studies suggest that the progestin hormones drospirenone and desogestrel may also increase the blood’s ability to clot. These newer-generation progestins are used in CHCs including Yaz, Yasmin, and Desogen.
Research indicates that the patch and vaginal ring have a higher risk of blood clots than most oral contraceptive pills. One study found that women using the vaginal ring were 1.9 times more likely to experience a blood clot than those taking combination birth control pills. In this study, women using the patch were 2.3 times more likely to experience a blood clot than those taking combination birth control pills. (The research compared the patch and vaginal ring to levonorgestrel-containing combined oral contraception.)
In 2011, the NWHN recommended that the Food and Drug Administration (FDA) reverse its approval of drospirenone pills (including Yaz, Yasmin, and Desogen) due to the method’s heightened risk of blood clots and lack of unique benefits over other contraceptive options. There are specific concerns about the health risks of Yasmin, which is manufactured by Bayer. The FDA has reprimanded Bayer for its misleading ads that overstated the pills’ benefits and downplayed risks, and for delaying reports about blood clots to the FDA during the approval process.
In 2012, the FDA reviewed studies on drospirenone-containing birth control and found the method may be associated with an increased risk of clots compared to other progestin-containing contraception. The FDA did not conclude there was a causal relationship, however. The science behind the risk of blood clots with these progestins is still emerging.
There are other contraceptive options that are preferable for people who are at increased risk of clots. In fact, the most effective contraception methods do not contain estrogen and are not associated with a higher blood clot risk. These include the arm implant (i.e., Nexplanon) and intrauterine devices (IUDs), such as ParaGard, Kyleena, Mirena, Skyla, and Liletta. Each of these methods has its own unique benefits and risks that potential users should consider.
In addition, Depo Provera, progestin-only pills, condoms, and diaphragms are all also estrogen-free, and safe for people with a high blood clot risk. Emergency contraception (such as Plan B, One-Step, and Take Action) does not contain estrogen, so it does not increase blood clot risks.
Yes. In addition to preventing unintended pregnancy, CHCs may reduce the risk of developing ovarian and endometrial cancer, heart disease, and ectopic pregnancy (a pregnancy occurring outside the uterus). CHCs can also reduce menstrual pain and heavy bleeding, facial hair growth, acne, and symptoms associated with premenstrual syndrome (PMS) and polycystic ovarian syndrome (PCOS).
CHCs carry very little risk for most people. In fact, CHCs are one of the most-studied and safest medications available today. The pill, patch, and vaginal ring each meets a unique need, and their availability is important in order to ensure that women can access a broad range of methods that suit their specific circumstances.
While the patch and vaginal ring both expose users to higher doses of hormones than pills, people may find the benefits of not having to take a pill every day to be worth the small increased risk. (However, as noted above, the NWHN believes that drospirenone should be taken off the market because the increased risk is not outweighed by an increased benefit.)
All contraceptive users need complete information about the risks and benefits of each potential method, so they can determine what method (or combination of methods) is best for them. If you are concerned about the increased risk of blood clots and other potential risks and benefits of various contraceptive options, talk with a qualified health care provider and/or pharmacist.
- The World Health Organization: Combined Hormonal Oral Contraception and Risk of Venous Thromboembolism (VTE)
- The Centers for Disease Control and Prevention: Deep Vein Thrombosis (DVT)/Pulmonary (PE) - Blood Clot Forming in a Vein
- The American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice: Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills
-  Ozaki A, Bartholomew JR, Venous Thromboembolism (Deep Venous Thrombosis & Pulmonary Embolism), Cleveland: Cleveland Clinic Center for Continuing Education, 2012.
-  U.S. Food & Drug Administration (FDA), FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone, Rockville (MD): FDA, 2013.
-  Allina A, “Contraceptive Safety Concerns: What’s a Responsible Feminist to do?” The Women’s Health Activist 2012; 37(3):4-5.
-  American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice, “Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills (Committee Opinion No. 540),” Obstet Gynecol 2012;120:1239–42.
-  Lidegaard Ø, Hougaard Nielsen L, Skovlund CW, and E Løkkegaard. “Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10,” BMJ 2012; 344:e2990.
-  Centers for Disease Control and Prevention (CDC), "Venous Thromboembolism (Blood Clots),” Atlanta: CDC, 2015.
-  Batur P, Female Contraception, Cleveland: Cleveland Clinic Center for Continuing Education, 2016.
This fact sheet is meant to provide current and potential contraceptive users with information to help weigh the risks and benefits of using hormonal contraception. Readers are encouraged to consult their health care providers and/or pharmacists for a more detailed discussion of the risks of using combined hormonal contraception.